Dr. Mulkerin's clinical practice is focused on gastrointestinal malignancies. He is actively involved in clinical research. He is a highly respected mentor and has extensive teaching experience. Dr. Mulkerin holds an important role in enhancing and advancing the Department of Medicine's footprint in...

Certified Specialties

Medical Oncology - American Board of Internal Medicine

Faculty Appointments

Professor - Department of Medicine, Hematology/Oncology (SMD)

Professor - Cancer Center - Joint

Credentials

Residency & Fellowship

Fellowship, Medical Oncology, University of Wisconsin Hospital and Clinics. 1996 - 1999

Residency, Internal Medicine, University of Wisconsin Hospital and Clinics. 1993 - 1996

Internship, Internal Medicine, University of Wisconsin Hospital and Clinics. 1992 - 1993

Education

MD | Thomas Jefferson University Hospital. 1992

Awards

Award for Service/Leadership Excellence. 2017 - 2018

UW Health Patient Experience Physician Champion Award. 2016

UW Health Physician Excellence Regional Services Award. 2015

UW Health Patient Experience Physician Champion Award. 2014

Best Doctor's in America. 2013 - 2021

Top Doctors: Madison Magazine. 2006

Hobart Armory Hare Honor Society. 1992

UW Hematology/Oncology Division/Department of Medicine.

Research

Clinical Trials

A Phase 1b/2 Trial of Immunotherapy With Avelumab and Pepinemab As Second Line For Patients With Metastatic Pancreatic Adenocarcinoma

Lead Researcher: Daniel L Mulkerin

This trial will assess the safety and tolerability of Pepinemab in combination with Avelumab in patients with metastatic pancreatic adenocarcinoma that has progressed after first line chemotherapy. Phase 2 will assess the efficacy of this combination...

A Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer

Lead Researcher: Daniel L Mulkerin

This phase III trial compares perioperative chemotherapy (given before and after surgery) versus adjuvant chemotherapy (given after surgery) for the treatment of pancreatic cancer that can be removed by surgery (removable/resectable). Chemotherapy dr...

Publications

Journal Articles

Mismatch Repair and Microsatellite Testing for Individuals With Colorectal Cancer.

Dhimal T, Colugnati F, Hilty Chu BK, Loria A, Cupertino P, Mulkerin D, Fleming FJ

JAMA oncology.. 2024 November 110 (11):1593-1595. Epub 1900 01 01.

Measuring Advanced Practice Provider Productivity at the National Comprehensive Cancer Network's Member Institutions.

Krause D, Sharrah K, Gross A, Bowers D, Mulkerin D, Brandt N, Kennedy K, Austin A, Begue A, Bell R, Raczyk C, Pickard T, Kubal T, Johnson D, Jeffries K, Dest V, Randall R, Sugalski J, Zecha G

Journal of the advanced practitioner in oncology.. 2022 July 13 (5):507-513. Epub 07/27/2022.

Supporting Structured Data Capture for Patients With Cancer: An Initiative of the University of Wisconsin Carbone Cancer Center Survivorship Program to Improve Capture of Malignant Diagnosis and Cancer Staging Data.

Emamekhoo H, Carroll CB, Stietz C, Pier JB, Lavitschke MD, Mulkerin D, Sesto ME, Tevaarwerk AJ

JCO clinical cancer informatics.. 2022 June 6 :e2200020. Epub 1900 01 01.

A Study of Advanced Practice Provider Staffing Models and Professional Development Opportunities at National Comprehensive Cancer Network Member Institutions.

Austin A, Jeffries K, Krause D, Sugalski J, Sharrah K, Gross A, Bowers D, Mulkerin D, Brandt N, Begue A, Bell R, Raczyk C, Pickard T, Johnson D, Dest V, Randall R, Zecha G, Kennedy K

Journal of the advanced practitioner in oncology.. 2021 September 12 (7):717-724. Epub 09/01/2021.

Microwave ablation for colorectal cancer metastasis to the liver: a single-center retrospective analysis.

Knott EA, Ziemlewicz TJ, Lubner SJ, Swietlik JF, Weber SM, Zlevor AM, Longhurst C, Hinshaw JL, Lubner MG, Mulkerin DL, Abbott DE, Deming D, LoConte NK, Uboha N, Couillard AB, Wells SA, Laeseke PF, Alexander ML, Lee FT

Journal of gastrointestinal oncology.. 2021 August 12 (4):1454-1469. Epub 1900 01 01.

Status of Cancer Care at Network Sites of the Nation's Academic Cancer Centers.

Gerson SL, Shaw K, Harrison LB, Holcombe RF, Hutchins L, Lee CB, Loehrer PJ, Mulkerin D, Purcell WT, Teston L, Weiner LM, Weiner GJ

Journal of the National Comprehensive Cancer Network : JNCCN.. 2021 March 1119 (6):726-732. Epub 03/11/2021.

A Phase 1 Dose Escalation Study of Neoadjuvant SBRT Plus Elective Nodal Radiation with Concurrent Capecitabine for Resectable Pancreatic Cancer.

Witt JS, Kuczmarska-Haas A, Lubner M, Reeder SB, Cho SY, Minter R, Weber S, Ronnekleiv-Kelly S, Abbott D, LoConte N, Mulkerin DL, Lubner SJ, Uboha NV, Deming D, Ritter MA, Mohindra P, Bassetti MF

International journal of radiation oncology, biology, physics.. 2021 February 1109 (2):458-463. Epub 09/14/2020.

Phase 1 dose escalation trial of TAS-102 (trifluridine/tipiracil) and temozolomide in the treatment of advanced neuroendocrine tumors.

Uboha NV, Lubner SJ, LoConte NK, Mulkerin DL, Eickhoff JC, Deming DA

Investigational new drugs.. 2020 October 38 (5):1520-1525. Epub 04/06/2020.

National Comprehensive Cancer Network Infusion Efficiency Workgroup Study: Optimizing Patient Flow in Infusion Centers.

Sugalski JM, Kubal T, Mulkerin DL, Caires RL, Moore PJ, Fiorarancio Fahy R, Gordon JN, Augustyniak CZ, Szymanski GM, Olsen M, Frantz DK, Quinn MA, Kidd SK, Krause DM, Carlson RW, Stewart FM

Journal of oncology practice. 2019 May 15 (5):e458-e466. Epub 04/09/2019.

Metastatic Bulk Independently Predicts Outcomes for EGFR Precision Targeting in Colorectal Cancer.

Kratz JD, Uboha NV, Lubner SJ, Mulkerin DL, Clipson L, Yi Y, Yu M, Matkowskyj KA, LoConte NK, Deming DA

Journal of the National Comprehensive Cancer Network : JNCCN.. 2018 December 16 (12):1442-1450. Epub 1900 01 01.

Pregnancy Screening in Patients With Cancer.

Gustafson AM, Goldfrank DJ, Dunson WA, Mulkerin DL, Caires RL, Eaton KD

Journal of the National Comprehensive Cancer Network : JNCCN.. 2018 January 16 (1):99-103. Epub 1900 01 01.

Utilization and evaluation of noncore chemotherapy regimens within an academic medical center.

Jared JR, Mably MS, Makielski R, Reed MP, Fallon MJ, Liu G, Mulkerin D, Callander NS

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.. 2017 October 23 (7):518-524. Epub 07/06/2016.

Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial.

Venook AP, Niedzwiecki D, Lenz HJ, Innocenti F, Fruth B, Meyerhardt JA, Schrag D, Greene C, O'Neil BH, Atkins JN, Berry S, Polite BN, O'Reilly EM, Goldberg RM, Hochster HS, Schilsky RL, Bertagnolli MM, El-Khoueiry AB, Watson P, Benson AB, Mulkerin DL, Mayer RJ, Blanke C

JAMA.. 2017 June 20317 (23):2392-2401. Epub 1900 01 01.

Multidisciplinary Optimization of Oral Chemotherapy Delivery at the University of Wisconsin Carbone Cancer Center.

Mulkerin DL, Bergsbaken JJ, Fischer JA, Mulkerin MJ, Bohler AM, Mably MS

Journal of oncology practice. 2016 October 12 (10):e912-e923. Epub 1900 01 01.

The Multidisciplinary Management of Colorectal Cancer: Present and Future Paradigms.

Sievers CK, Kratz JD, Zurbriggen LD, LoConte NK, Lubner SJ, Uboha N, Mulkerin D, Matkowskyj KA, Deming DA

Clinics in colon and rectal surgery.. 2016 September 29 (3):232-8. Epub 1900 01 01.

A Phase II Trial of a Histone Deacetylase Inhibitor Panobinostat in Patients With Low-Grade Neuroendocrine Tumors.

Jin N, Lubner SJ, Mulkerin DL, Rajguru S, Carmichael L, Chen H, Holen KD, LoConte NK

The oncologist.. 2016 July 21 (7):785-6. Epub 06/03/2016.

A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancer.

Deming DA, Cavalcante LL, Lubner SJ, Mulkerin DL, LoConte NK, Eickhoff JC, Kolesar JM, Fioravanti S, Greten TF, Compton K, Doyle AG, Wilding G, Duffy A, Liu G

Investigational new drugs.. 2016 April 34 (2):168-75. Epub 12/14/2015.

A phase I study to determine the maximum tolerated dose and safety of oral LR-103 (1?,24(S)Dihydroxyvitamin D2) in patients with advanced cancer.

Wisinski KB, Ledesma WM, Kolesar J, Wilding G, Liu G, Douglas J, Traynor AM, Albertini M, Mulkerin D, Bailey HH

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.. 2015 December 21 (6):416-24. Epub 07/01/2014.

Precision medicine in colorectal cancer: the molecular profile alters treatment strategies.

Tran NH, Cavalcante LL, Lubner SJ, Mulkerin DL, LoConte NK, Clipson L, Matkowskyj KA, Deming DA

Therapeutic advances in medical oncology.. 2015 September 7 (5):252-262. Epub 07/05/2015.

A phase II study of sorafenib, oxaliplatin, and 2 days of high-dose capecitabine in advanced pancreas cancer.

Makielski RJ, Lubner SJ, Mulkerin DL, Traynor AM, Groteluschen D, Eickhoff J, LoConte NK

Cancer chemotherapy and pharmacology.. 2015 August 76 (2):317-23. Epub 06/12/2015.

A multicenter phase 1 study of ? -secretase inhibitor RO4929097 in combination with capecitabine in refractory solid tumors.

LoConte NK, Razak AR, Ivy P, Tevaarwerk A, Leverence R, Kolesar J, Siu L, Lubner SJ, Mulkerin DL, Schelman WR, Deming DA, Holen KD, Carmichael L, Eickhoff J, Liu G

Investigational new drugs.. 2015 February 33 (1):169-76. Epub 10/17/2014.

A phase I study of sorafenib, oxaliplatin and 2 days of high dose capecitabine in advanced pancreatic and biliary tract cancer: a Wisconsin oncology network study.

LoConte NK, Holen KD, Schelman WR, Mulkerin DL, Deming DA, Hernan HR, Traynor AM, Goggins T, Groteluschen D, Oettel K, Robinson E, Lubner SJ

Investigational new drugs.. 2013 August 31 (4):943-8. Epub 12/21/2012.

Phase I study of pazopanib in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study.

Shibata SI, Chung V, Synold TW, Longmate JA, Suttle AB, Ottesen LH, Lenz HJ, Kummar S, Harvey RD, Hamilton AL, O'Neil BH, Sarantopoulos J, LoRusso P, Rudek MA, Dowlati A, Mulkerin DL, Belani CP, Gandhi L, Lau SC, Ivy SP, Newman EM

Clinical cancer research : an official journal of the American Association for Cancer Research.. 2013 July 119 (13):3631-9. Epub 05/07/2013.

A phase II study of capecitabine and lapatinib in advanced refractory colorectal adenocarcinoma: A Wisconsin Oncology Network study.

Frank D, Jumonville A, Loconte NK, Schelman WR, Mulkerin D, Lubner S, Richter K, Winterle N, Wims MB, Dietrich L, Winkler JM, Volk M, Kim K, Holen KD

Journal of gastrointestinal oncology.. 2012 June 3 (2):90-6. Epub 1900 01 01.

Pharmacokinetics and safety of bortezomib in patients with advanced malignancies and varying degrees of liver dysfunction: phase I NCI Organ Dysfunction Working Group Study NCI-6432.

LoRusso PM, Venkatakrishnan K, Ramanathan RK, Sarantopoulos J, Mulkerin D, Shibata SI, Hamilton A, Dowlati A, Mani S, Rudek MA, Takimoto CH, Neuwirth R, Esseltine DL, Ivy P

Clinical cancer research : an official journal of the American Association for Cancer Research.. 2012 May 1518 (10):2954-63. Epub 03/06/2012.

Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study.

Leal TB, Remick SC, Takimoto CH, Ramanathan RK, Davies A, Egorin MJ, Hamilton A, LoRusso PA, Shibata S, Lenz HJ, Mier J, Sarantopoulos J, Mani S, Wright JJ, Ivy SP, Neuwirth R, von Moltke L, Venkatakrishnan K, Mulkerin D

Cancer chemotherapy and pharmacology.. 2011 December 68 (6):1439-47. Epub 04/09/2011.

Retrospective analysis of satraplatin in patients with metastatic urothelial cancer refractory to standard platinum-based chemotherapy.

Galsky MD, Seng S, Camacho LH, Chiorean EG, Mulkerin D, Hong DS, Oh WK, Bajorin DF

Clinical genitourinary cancer.. 2011 September 9 (1):27-30. Epub 06/22/2011.

A preclinical and clinical study of lithium in low-grade neuroendocrine tumors.

Lubner SJ, Kunnimalaiyaan M, Holen KD, Ning L, Ndiaye M, Loconte NK, Mulkerin DL, Schelman WR, Chen H

The oncologist.. 2011 16 (4):452-7. Epub 03/10/2011.

A pilot phase II study of valproic acid for treatment of low-grade neuroendocrine carcinoma.

Mohammed TA, Holen KD, Jaskula-Sztul R, Mulkerin D, Lubner SJ, Schelman WR, Eickhoff J, Chen H, Loconte NK

The oncologist.. 2011 16 (6):835-43. Epub 05/31/2011.

Randomized trial of adjuvant zoledronic acid in postmenopausal women with high-risk breast cancer.

Leal T, Tevaarwerk A, Love R, Stewart J, Binkley N, Eickhoff J, Parrot B, Mulkerin D

Clinical breast cancer.. 2010 December 110 (6):471-6. Epub 1900 01 01.

A phase II study of oxaliplatin, 5-fluorouracil, leucovorin, and high-dose capecitabine in patients with metastatic colorectal cancer.

Lubner SJ, Loconte NK, Holen KD, Schelman W, Thomas JP, Jumonville A, Eickhoff JC, Seo S, Mulkerin DL

Clinical colorectal cancer.. 2010 July 9 (3):157-61. Epub 1900 01 01.

Dose-escalation study of fixed-dose rate gemcitabine combined with capecitabine in advanced solid malignancies.

Attia S, Morgan-Meadows S, Holen KD, Bailey HH, Eickhoff JC, Schelman WR, Traynor AM, Mulkerin DL, Campbell TC, McFarland TA, Huie MS, Cleary JF, Tevaarwerk AJ, Alberti DB, Wilding G, Liu G

Cancer chemotherapy and pharmacology.. 2009 June 64 (1):45-51. Epub 10/08/2008.

A phase I trial of CEP-701 + gemcitabine in patients with advanced adenocarcinoma of the pancreas.

Chan E, Mulkerin D, Rothenberg M, Holen KD, Lockhart AC, Thomas J, Berlin J

Investigational new drugs.. 2008 June 26 (3):241-7. Epub 01/24/2008.

Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of liver dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group.

Ramanathan RK, Egorin MJ, Takimoto CH, Remick SC, Doroshow JH, LoRusso PA, Mulkerin DL, Grem JL, Hamilton A, Murgo AJ, Potter DM, Belani CP, Hayes MJ, Peng B, Ivy SP,

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2008 February 126 (4):563-9. Epub 1900 01 01.

Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group.

Gibbons J, Egorin MJ, Ramanathan RK, Fu P, Mulkerin DL, Shibata S, Takimoto CH, Mani S, LoRusso PA, Grem JL, Pavlick A, Lenz HJ, Flick SM, Reynolds S, Lagattuta TF, Parise RA, Wang Y, Murgo AJ, Ivy SP, Remick SC,

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2008 February 126 (4):570-6. Epub 1900 01 01.

Biologic study of the effects of octreotide-LAR on growth hormone in unresectable and metastatic hepatocellular carcinoma.

Attia S, Holen KD, Thomas JP, Richie K, Dzelak T, Teeter K, Warren D, Bilger A, Fine J, Eickhoff J, Drinkwater N, Mulkerin D, Morgan-Meadows S

Clinical advances in hematology & oncology : H&O.. 2008 January 6 (1):44-54. Epub 1900 01 01.

Oxaliplatin pharmacokinetics and pharmacodynamics in adult cancer patients with impaired renal function.

Takimoto CH, Graham MA, Lockwood G, Ng CM, Goetz A, Greenslade D, Remick SC, Sharma S, Mani S, Ramanathan RK, Synold TW, Doroshow JH, Hamilton A, Mulkerin DL, Ivy P, Egorin MJ, Grem JL

Clinical cancer research : an official journal of the American Association for Cancer Research.. 2007 August 1513 (16):4832-9. Epub 1900 01 01.

Phase I trial of weekly paclitaxel and BMS-214662 in patients with advanced solid tumors.

Bailey HH, Alberti DB, Thomas JP, Mulkerin DL, Binger KA, Gottardis MM, Martell RE, Wilding G

Clinical cancer research : an official journal of the American Association for Cancer Research.. 2007 June 1513 (12):3623-9. Epub 05/17/2007.

Dose-escalating and pharmacologic study of oxaliplatin in adult cancer patients with impaired hepatic function: a National Cancer Institute Organ Dysfunction Working Group study.

Synold TW, Takimoto CH, Doroshow JH, Gandara D, Mani S, Remick SC, Mulkerin DL, Hamilton A, Sharma S, Ramanathan RK, Lenz HJ, Graham M, Longmate J, Kaufman BM, Ivy P,

Clinical cancer research : an official journal of the American Association for Cancer Research.. 2007 June 1513 (12):3660-6. Epub 1900 01 01.

A phase II trial of gemcitabine, 5-fluorouracil and leucovorin in advanced esophageal carcinoma.

Morgan-Meadows S, Mulkerin D, Berlin JD, Kim K, Bailey H, Saphner T, Jumonville A, Hansen R, Ahuja H, McFarland T, Thomas JP

Oncology.. 2005 69 (2):130-4. Epub 08/23/2005.

Couch LS, Groteluschen DL, Stewart JA, Mulkerin DL

Clinical colorectal cancer.. 2003 August 3 (2):121-3. Epub 1900 01 01.

Pharmacology of oxaliplatin in solid tumor patients with hepatic dysfunction: a preliminary report of the National Cancer Institute Organ Dysfunction Working Group.

Doroshow JH, Synold TW, Gandara D, Mani S, Remick SC, Mulkerin D, Hamilton A, Sharma S, Ramanathan RK, Lenz HJ, Graham M, Longmate J, Takimoto CH, Ivy P

Seminars in oncology.. 2003 August 30 (4 Suppl 15):14-9. Epub 1900 01 01.

Administration of oxaliplatin to patients with renal dysfunction: a preliminary report of the national cancer institute organ dysfunction working group.

Takimoto CH, Remick SC, Sharma S, Mani S, Ramanathan RK, Doroshow JH, Hamilton A, Mulkerin D, Graham M, Lockwood GF, Ivy P, Egorin M, Greenslade D, Goetz A, Grem JL

Seminars in oncology.. 2003 August 30 (4 Suppl 15):20-5. Epub 1900 01 01.

Dose-escalating and pharmacological study of oxaliplatin in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study.

Takimoto CH, Remick SC, Sharma S, Mani S, Ramanathan RK, Doroshow J, Hamilton A, Mulkerin D, Graham M, Lockwood GF, Ivy P, Egorin M, Schuler B, Greenslade D, Goetz A, Knight R, Thomas R, Monahan BP, Dahut W, Grem JL,

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2003 July 1521 (14):2664-72. Epub 1900 01 01.

Phase I study of eniluracil, oral 5-fluororacil and gemcitabine in patients with advanced malignancy.

Morgan-Meadows S, Thomas JP, Mulkerin D, Berlin JD, Bailey H, Binger K, Volkman J, Alberti D, Feierabend C, Marrocha R, Arzoomanian RZ, Wilding G

Investigational new drugs.. 2002 November 20 (4):377-82. Epub 1900 01 01.

Phase II trial of perillyl alcohol in patients with metastatic colorectal cancer.

Meadows SM, Mulkerin D, Berlin J, Bailey H, Kolesar J, Warren D, Thomas JP

International journal of gastrointestinal cancer.. 2002 32 (2-3):125-8. Epub 1900 01 01.

Ratings & Comments

At URMC, we believe that patients should be empowered to make the right decisions regarding their personal healthcare. To do so, transparency is critical. URMC partners with Press Ganey, to survey our patients about all aspects of their care experience. We are now putting this pertinent information at your fingertips by displaying star ratings for our providers along with anonymous patient comments on our website. This will help you make better-informed choices about how and with whom you seek care. Click here to learn more about the surveys used to generate this vital information. Learn more about our survey process.

Ratings

Care provider's discussion of any proposed treatment (options, risks, benefits, etc.)

4.9

Likelihood of recommending this care provider to others

4.9

Explanations the care provider gave you about your problem or condition

4.9

Care provider's efforts to include you in decisions about your care

4.9

Concern the care provider showed for your questions or worries

5.0

Patient Comments

5.0

Drs. Mulkerin, Temple and Moore made extra time for me and gone above and beyond to collaborate on my case and keep me informed.

Dec 15, 2024

5.0

Nice job

Nov 29, 2024

5.0

All good

Oct 20, 2024

5.0

Excellent attention and care

Sep 12, 2024

5.0

Dr. Mulkerin is an exceptional physician. He is knowledgeable, forthright yet kind with exceptional communication skills.

Jul 29, 2024

5.0

Dr Mulkerin is the best!

Jul 27, 2024

5.0

Dr Mulkerin is very engaged; great listener; well-prepared & calming

Jul 21, 2024

5.0

Dr. Mulkerin is awesome

Jul 21, 2024

5.0

Dr. Mulkerin is an excellent practitioner, always caring and knowledgeable. I would definitely recommend him to anyone needing a professional, compassionate oncologist.

Jun 08, 2024

4.8

Always listens and addresses all of my concerns

May 24, 2024

5.0

My Doctor is great

Mar 22, 2024

5.0

Stage 4 colon cancer and chemo for life, not many options as good as Dr Mulkerin and the Webster Wilmot facility.

Nov 29, 2023

5.0

Dr. Mulkerin has best bedside manner & expertise re: my oncology.

Aug 02, 2023

4.2

[...] I found him very professional & knowledgeable.

Jun 23, 2023

5.0

Dr. and staff very professional.

Apr 17, 2023

5.0

Love my team. They are great!

Feb 23, 2023

5.0

Dr. Mulkerin is outstanding!

Feb 02, 2023

5.0

I knew someone that had cancer I would recommend this doctor.

Jan 23, 2023